1. Home
  2. ICUI vs OGN Comparison

ICUI vs OGN Comparison

Compare ICUI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • OGN
  • Stock Information
  • Founded
  • ICUI 1984
  • OGN 1923
  • Country
  • ICUI United States
  • OGN United States
  • Employees
  • ICUI N/A
  • OGN N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • OGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICUI Health Care
  • OGN Health Care
  • Exchange
  • ICUI Nasdaq
  • OGN Nasdaq
  • Market Cap
  • ICUI 3.0B
  • OGN 2.7B
  • IPO Year
  • ICUI 1992
  • OGN N/A
  • Fundamental
  • Price
  • ICUI $133.13
  • OGN $10.69
  • Analyst Decision
  • ICUI Buy
  • OGN Hold
  • Analyst Count
  • ICUI 6
  • OGN 4
  • Target Price
  • ICUI $186.60
  • OGN $18.00
  • AVG Volume (30 Days)
  • ICUI 314.3K
  • OGN 3.7M
  • Earning Date
  • ICUI 11-11-2025
  • OGN 10-30-2025
  • Dividend Yield
  • ICUI N/A
  • OGN 0.75%
  • EPS Growth
  • ICUI N/A
  • OGN N/A
  • EPS
  • ICUI N/A
  • OGN 2.69
  • Revenue
  • ICUI $2,372,504,000.00
  • OGN $6,281,000,000.00
  • Revenue This Year
  • ICUI N/A
  • OGN N/A
  • Revenue Next Year
  • ICUI N/A
  • OGN $1.36
  • P/E Ratio
  • ICUI N/A
  • OGN $3.97
  • Revenue Growth
  • ICUI 2.96
  • OGN N/A
  • 52 Week Low
  • ICUI $107.00
  • OGN $8.01
  • 52 Week High
  • ICUI $196.26
  • OGN $21.06
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 60.24
  • OGN 67.44
  • Support Level
  • ICUI $121.61
  • OGN $10.13
  • Resistance Level
  • ICUI $136.61
  • OGN $10.58
  • Average True Range (ATR)
  • ICUI 3.76
  • OGN 0.36
  • MACD
  • ICUI 1.09
  • OGN 0.15
  • Stochastic Oscillator
  • ICUI 78.47
  • OGN 98.56

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About OGN Organon & Co.

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Share on Social Networks: